Moonlake
formerly MoonLake ImmunotherapeuticsIPONext-level Nanobody® therapies to elevate patient care
Public · Zug, Switzerland · Founded 2021
- Headquarters
- Zug
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
- Website
- moonlaketx.com
- Last Round
- Series AOct 2021
- Rounds
- 2
- Type
- Public
About
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company registered in March 2021 as a Swiss stock corporation and headquartered in Zug, Switzerland. The company is developing Sonelokimab, a novel Nanobody that independently inhibits IL-17A and IL-17F to treat inflammatory diseases including hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). MoonLake listed on Nasdaq under ticker MLTX in April 2022 following a de-SPAC merger with Helix Acquisition Corp.
Summary
Moonlake is a Biotech company based in Zug, Switzerland, founded in 2021. Its most recent funding was a Series A round in Oct 2021. Investors include Hercules Capital, Helix Acquisition Corp. and Cormorant Asset Management.
Tech & App Stack
5 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding & Exit History
Mar 2025
Sign up to see all 7 events
Funding: Series A. Amounts, valuations, and investors where available.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/moonlake"><img src="https://indexed.vc/api/badge/company/moonlake" alt="Moonlake on Indexed.vc" width="260" height="76" /></a>